Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis

References

• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404.
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiat. 2015;86(9):1036–1043.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73–85.
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA. 2002;99(Suppl 4):16427–16432.
   PubMedGoogle Scholar
• Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver-transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113–1116.
   PubMed Web of Science ®Google Scholar
• Wilczek HE, Larsson M, Ericzon BG, FAPWTR Long-term data from the familial amyloidotic polyneuropathy world transplant registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193–195.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Adams D, Tournev IL, Taylor MS, The HELIOS-A Collaborators, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022:1–9.
   PubMed Web of Science ®Google Scholar
• Maia LF, Magalhaes R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiat. 2015;86(2):159–167.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87(8):773–781.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Andreou S, Aloizou AM, et al. The frequency of Central nervous system complications in the cypriot cohort of ATTRV30M neuropathy transplanted patients. Neurol Sci. 2020;41(5):1163–1170.
   PubMed Web of Science ®Google Scholar
• Salvi F, Pastorelli F, Plasmati R, et al. Brain microbleeds 12 years after orthotopic liver transplantation in Val30Met amyloidosis. J Stroke Cerebrovasc Dis. 2015;24(6):e149–e151.
   PubMed Web of Science ®Google Scholar
• Freitas Castro V, Nascimento Alves P, Franco AC, et al. Cognitive impairment in liver transplanted patients with transthyretin-related hereditary amyloid polyneuropathy. Amyloid. 2017;24(2):110–114.
   PubMed Web of Science ®Google Scholar
• Martins da Silva A, Cavaco S, Fernandes J, et al. Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol. 2018;265(2):299–307.
   PubMed Web of Science ®Google Scholar
• LeVine H. 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274–284.
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.
   PubMed Web of Science ®Google Scholar
• Ezawa N, Katoh N, Oguchi K, et al. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur J Nucl Med Mol Imag. 2018;45(3):452–461.
   PubMed Web of Science ®Google Scholar
• Takasone K, Katoh N, Takahashi Y, et al. Non-invasive detection and differentiation of cardiac amyloidosis using (99m)Tc-pyrophosphate scintigraphy and (11)C-Pittsburgh compound B PET imaging. Amyloid. 2020;27(4):266–274.
   PubMed Web of Science ®Google Scholar
• Lundqvist R, Lilja J, Thomas BA, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472–1478.
   PubMed Web of Science ®Google Scholar
• Hammers DB, Atkinson TJ, Dalley BC, et al. Relationship between (18)F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults. Clin Neuropsychol. 2017;31(3):531–543.
   PubMed Web of Science ®Google Scholar
• Hammers DB, Atkinson TJ, Dalley BCA, et al. Amyloid positivity using [18F]Flutemetamol-PET and cognitive deficits in nondemented community-dwelling older adults. Am J Alzheimers Dis Other Demen. 2017;32(6):320–328.
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin-type cerebral amyloid angiopathy: a serious complication in post-transplant patients with familial amyloid polyneuropathy. J Neurol Neurosurg Psychiat. 2015;86(2):124.
   PubMed Web of Science ®Google Scholar
• Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology. 2003;60(10):1625–1630.
   PubMed Web of Science ®Google Scholar
• Schweitzer K, Ehmann D, Garcia R, et al. Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His. Can J Ophthalmol. 2009;44(3):317–319.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Andersen O, Aronsson T, et al. Report of five rare or previously unknown amyloidogenic transthyretin mutations disclosed in Sweden. Amyloid. 2009;16(4):208–214.
   PubMed Web of Science ®Google Scholar
• Ziskin JL, Greicius MD, Zhu W, et al. Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia. Acta Neuropathol Commun. 2015;3:43.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Fukushima T, Kodama S, et al. A case of cerebral amyloid angiopathy-type hereditary ATTR amyloidosis with Y69H (p.Y89H) variant displaying transient focal neurological episodes as the main symptom. Amyloid. 2019;26(4):251–252.
   PubMed Web of Science ®Google Scholar
• Douglass C, Suvarna K, Reilly MM, et al. A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia. J Neurol Neurosurg Psychiat. 2007;78(2):193–195.
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Dickson DW, Benson MD. A new transthyretin mutation associated with leptomeningeal amyloidosis. Amyloid. 2011;18(Suppl 1):160–162.
   PubMedGoogle Scholar
• Mitsuhashi S, Yazaki M, Tokuda T, et al. Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis. Amyloid. 2005;12(4):216–225.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ohashi N, Takasone K, et al. CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. Amyloid. 2022;29(3):190–196. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Sousa L, Coelho T, Taipa R. CNS involvement in hereditary transthyretin amyloidosis. Neurology. 2021;97(24):1111–1119.
   PubMed Web of Science ®Google Scholar
• Wange N, Anan I, Ericzon BG, et al. Atrial fibrillation and central nervous complications in liver transplanted hereditary transthyretin amyloidosis patients. Transplantation. 2018;102(2):e59–e66.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and Meta-analysis. Stroke. 2012;43(9):2324–2330.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Baron JC, Werring DJ. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. Int J Stroke. 2013;8(2):105–108.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Law R, Werring DJ. Amyloid “spells” trouble. Lancet. 2012;380(9853):1620.
   PubMed Web of Science ®Google Scholar
• Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke. 2015;17(1):17–30.
   PubMed Web of Science ®Google Scholar
• Uneus EI, Wilhelmsson C, Bäckström D, et al. Cerebellar and cerebral amyloid visualized by [(18)F]flutemetamol PET in Long-Term hereditary V30M (p.V50M) transthyretin amyloidosis survivors. Front Neurol. 2022;13:816636.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120–128.
   PubMed Web of Science ®Google Scholar
• Sant’Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Commun. 2016;7:10787.
   PubMed Web of Science ®Google Scholar
• Pinheiro F, Varejão N, Esperante S, et al. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. FEBS J. 2021;288(1):310–324.
   PubMed Web of Science ®Google Scholar
• Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20(3):142–150.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253–261.
   PubMed Web of Science ®Google Scholar
• Altmann A, Tian L, Henderson VW, et al. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563–573.
   PubMed Web of Science ®Google Scholar